Review dosing recommendations and safety information for an atypical antipsychotic for schizophrenia, bipolar I disorder, and adjunctive major depressive disorder.
Atypical antipsychotics can be associated with changes in metabolic parameters and weight gain in patients receiving adjunctive treatment to antidepressants for major depressive disorder (MDD). This video reviews the data on metabolic and...
Atypical antipsychotics can be associated with changes in metabolic parameters and weight gain in patients receiving adjunctive treatment to antidepressants for major depressive disorder (MDD). This video reviews the data on metabolic and...
The use of atypical antipsychotics in the treatment of bipolar I disorder (BP-1) can be associated with changes in metabolic parameters and weight. This video provides an overview of the key efficacy and safety data, including metabolic and...
The use of atypical antipsychotics in the treatment of bipolar I disorder (BP-1) can be associated with changes in metabolic parameters and weight. This video provides an overview of the key efficacy and safety data, including metabolic and...
The use of atypical antipsychotics in the treatment of schizophrenia can be associated with changes in metabolic parameters and weight. This video reviews the safety data on metabolic and weight changes from key clinical trials for...
The use of atypical antipsychotics in the treatment of schizophrenia can be associated with changes in metabolic parameters and weight. This video reviews the safety data on metabolic and weight changes from key clinical trials for...
Through this short video, you’ll learn more about akathisia and tardive dyskinesia as being possible movement disorder side effects related to the adjunctive use of atypical antipsychotics in adult patients with major depressive disorder.
Through this short video, you’ll learn more about akathisia and tardive dyskinesia as being possible movement disorder side effects related to the adjunctive use of atypical antipsychotics in adult patients with major depressive disorder.
This video, featuring Roger McIntyre, MD, FRCPC, highlights anxiety and anhedonia symptoms as possible residual symptoms that may be experienced by adult MDD patients with inadequate response to antidepressant therapy.
This video, featuring Roger McIntyre, MD, FRCPC, highlights anxiety and anhedonia symptoms as possible residual symptoms that may be experienced by adult MDD patients with inadequate response to antidepressant therapy.
